Fosun seals $1.1bn deal for India drugmaker
复星医药收购印度同行
广州医药翻译公司：同意收购Gland Pharma 86%的股权，将成中资企业迄今对印度企业的最大规模收购交易。
Shanghai Fosun Pharma has agreed to pay $1.1bn for an 86 per cent stake in Indian drugmaker Gland Pharma, in the largest Indian corporate takeover by a Chinese company.
上海复星医药(Shanghai Fosun Pharmahas)同意斥资11亿美元收购印度制药商Gland Pharma 86%的股权，这是中国企业收购印度企业规模最大的一笔交易。广州医药翻译公司。
The deal is the biggest acquisition by Hong Kong-listed Fosun since the mysterious disappearance for several days last year of Guo Guangchan, the group’s chairman, in connection with an anti-corruption investigation in China.
该交易是在香港上市的复星集团(Fosun)自去年董事长郭广昌神秘失踪数天以来最大的一笔收购。郭广昌失联与中国一项反腐调查有关。
Yesterday’s deal — which values Gland at $1.35bn — also provides a lucrative exit for private equity firm KKR, which three years ago paid $200m for a 38 per cent stake in the Hyderabad-based drugmaker and is selling its full holding.
昨日交易对Gland估值13.5亿美元，它也让私人股本集团KKR能够盈利退出，后者3年前用2亿美元收购了这家总部位于海德拉巴的制药商38%的股份，此次出售其全部持股。
